DecellularizedWholeOrganScaffolds

Why It Matters

Over 100,000 people are on organ transplant waiting lists in the US alone, with thousands dying annually due to organ scarcity and rejection risks. When successful, patients needing organ transplants could receive new organs grown from their own cells, eliminating the need for immunosuppressants and significantly reducing rejection rates, leading to healthier, longer lives. Transplant centers and patients needing organs win; pharmaceutical companies selling immunosuppressants might see reduced demand. Challenges include achieving full functional recellularization, preventing scaffold collapse, and scaling up the complex decellularization and recellularization processes, along with stringent regulatory approval for human trials. Clinical trials for simpler structures might begin in 5-10 years, with complex solid organs potentially 15-25 years away. Research groups globally, particularly in the US and Europe (e.g., Karolinska Institutet), are actively pursuing this. A second-order consequence could be the ethical implications of using animal-derived scaffolds for human organs, despite decellularization, and the potential for new diseases if residual xenogenic components persist.